<qa>  What is the name of the lab that will be collected at Visit 1?At Visit 1 Baseline following Informed Consent, a physical and neurological exam, baseline electrocardiogram ECG, and vital signs will be completed. A urine pregnancy test will be collected by all subjects of childbearing potential. Routine labs electrolyte panel with creatinine, alanine aminotransferase ALT aspartate aminotransferase AST, a luteinizing hormone LH lab for menstrual cycle staging and a baseline saliva sample for CGRP, estrogen, cortisol, VIP, a-amylase, PGI2, PGE2 and β-endorphin analysis will be collected. Subjects should be headache-free at Visit 1. A medical, headache, and medication history will be collected on all subjects and eligible subjects will be randomized 1:1 to Group A or Group B. Group A will receive TreximetTM sumatriptan succinate 85 milligrams mg and naproxen sodium 500 mg 1 tablet. Group B will be provided 1 matching placebo tablet. Subjects will be instructed to not start study medication until notified by study staff that lab results were normal and they are eligible to proceed. Subjects will be instructed to treat as early as possible following the onset of a typical menstrual headache. Groups A and B will be provided with TreximetTM 1 tablet for rescue between 2 and 24 hours for persistent or recurring headache. Subjects will receive a Diary and instructions on Digital Versatile Disc DVD regarding documentation. Migraine associated symptoms ie nausea, vomiting, light sensitivity, or sound sensitivity will be collected as well as sleeplessness, difficulty thinking other bodily pain, and menstrual associated symptoms to include intensity of menstrual cramps. 